Phase 3 N=70 Randomized Quadruple-blind Treatment

Iloprost Power 15 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT00709956 ↗

Enrolled (actual)

Serious AEs

1.6%

Results posted

Oct 2012

Primary outcome: Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: iloprost (5 µg) (Drug); placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Actelion
Primary completion: Aug 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY 6-minute-walk Distance (6MWD)	330.0; 328.6	0.7883
SECONDARY Borg Dyspnea Score	3.5; 3.4	—

Summary

Patients with symptomatic idiopathic pulmonary arterial hypertension (IPAH), or familial pulmonary arterial hypertension (FPAH) or pulmonary hypertension associated with Human immunodeficiency virus (HIV) or drugs/toxins in New York Heart Association (NYHA) functional class II to IV at baseline, naive to PAH treatment or currently being treated with a stable dose of either bosentan, ambrisentan or sildenafil will be enrolled in the PROWESS 15 study. This randomized, double blind, placebo-controlled, crossover, and single-dose study will determine whether a single inhaled dose of iloprost using the power 15 disc improves exercise capacity compared to placebo in patients with pulmonary arterial hypertension (PAH).

Eligibility Criteria

Inclusion Criteria

Signed informed consent prior to initiation of any study mandated procedure,
Patients with symptomatic idiopathic, or familial pulmonary arterial hypertension or pulmonary hypertension associated with human immunodeficiency virus (HIV) or drugs/toxins in NYHA functional class II to IV.
Women of childbearing potential must have a negative urine pregnancy test and must use an adequate method of contraception during the study and for 28 days after discontinuation of the study drug.

Exclusion Criteria

Pulmonary arterial hypertension related to any condition other than those specified in the inclusion criteria,
Pulmonary arterial hypertension associated with significant venous or capillary involvement (Pulmonary capillary wedge pressure (PCWP) > 15 mmHg),
Known pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis,
Moderate to severe obstructive lung disease: forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) 160 mmHg or diastolic blood pressure > 100 mmHg on repeated measurement),
Systolic blood pressure 2.5 mg/dL (221 μmol/L) or ongoing dialysis,
Clinically relevant bleeding disorder or active bleeding,
For those patients on monotherapy, any contraindication to bosentan, ambrisentan, or sildenafil, according to product label,
Known hypersensitivity to iloprost or any of its excipients.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00709956). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.